SecBot SecBot
SECBOTREPLAY Home › Report › IMCR

IMCR · Immunocore announced it has achieved target enrollment of 540 patients…

Immunocore Holdings plc · 8-K filed Sep 14, 2026 at 07:15 ET

At the news

BULLISHIMPACT 6/10

8-K filed Sep 14, 2026 at 07:15 ET

Immunocore announced it has achieved target enrollment of 540 patients in its Phase 3 TEBE-AM registrational trial evaluating tebentafusp (KIMMTRAK) in previously treated advanced melanoma. Topline overall survival data is expected as early as end of 2026. This is a positive clinical milestone that de-risks the trial timeline but provides no efficacy data yet.

  • Target enrollment of 540 patients achieved in Phase 3 TEBE-AM trial of tebentafusp in previously treated advanced melanoma
  • Topline overall survival data expected as early as end of 2026
  • Trial evaluates tebentafusp as monotherapy and in combination with pembrolizumab vs investigator's choice
  • Primary endpoint is overall survival

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access